Welcome to our dedicated page for Bioceres Crop Solutions news (Ticker: BIOX), a resource for investors and traders seeking the latest updates and insights on Bioceres Crop Solutions stock.
Bioceres Crop Solutions Corp (BIOX) delivers innovative agricultural technologies through integrated seed development, crop protection solutions, and biological nutrition products. This news hub provides stakeholders with essential updates about the company's advancements in sustainable farming solutions.
Access official press releases and curated news covering product launches, regulatory milestones, partnership announcements, and financial disclosures. Investors will find timely updates on BIOX's drought-tolerant seed technologies, biological crop inputs, and global market expansions.
Key content includes earnings reports, R&D breakthroughs in biotechnology, sustainability initiatives, and strategic collaborations. All materials are sourced from verified corporate communications to ensure accuracy and compliance with financial disclosure standards.
Bookmark this page for streamlined access to BIOX's latest developments in agricultural innovation. Regularly updated content supports informed analysis of the company's position in the agtech sector.
Bioceres Crop Solutions Corp. (NASDAQ: BIOX) announced the successful integration of Marrone Bio Innovations, Inc. (NASDAQ: MBII), valued at approximately $207 million. The merger, approved with 99.74% of votes on July 8, 2022, enhances Bioceres's position in sustainable agricultural solutions. MBI will operate as ProFarm, integrating its operational capabilities while leveraging expertise from former key employees. Changes in leadership include the addition of MBI directors to Bioceres's Board. This acquisition aims to foster a carbon-neutral agricultural landscape through innovative biological solutions.
Bioceres Crop Solutions Corp. (NASDAQ: BIOX) announced the FDA's conclusion of its evaluation of HB4® Wheat, indicating no further safety questions. This marks a crucial step toward commercialization in the U.S., pending USDA approval. The United States ranks fifth in wheat production, with HB4® Wheat already authorized in Argentina and recent approvals in Brazil, Colombia, Australia, and New Zealand. The HB4® technology significantly boosts wheat yields by 20% in water-limited conditions, promoting sustainable agricultural practices.
Bioceres Crop Solutions Corp. (NASDAQ: BIOX) will participate in the ROTH 8th Annual London Conference from June 21-23, 2022, held at the InterContinental London Park Lane. CEO Federico Trucco and CFO Enrique Lopez Lecube are set to engage in one-on-one meetings to discuss the company’s fiscal Q3 2022 financial results and its merger agreement with Marrone Bio Innovations. For details about the conference or to connect with the company, interested parties can contact ROTH representatives or reach out via email.
Bioceres Crop Solutions Corp. (NASDAQ: BIOX) reported a strong fiscal third quarter 2022, with comparable revenues rising 72% to $60.1 million. The company achieved key regulatory approval for HB4 Soy in China, enabling commercialization in multiple countries. EBITDA targets for HB4 Soy in FY25 are projected at $20-25 million. Additionally, HB4 Wheat received approval in Colombia, Australia, and New Zealand, with expected revenues of $10-12 million for the upcoming planting season. The merger with Marrone Bio Innovations is set to close in Q1 FY23.
Bioceres Crop Solutions Corp. (NASDAQ: BIOX) is set to discuss its fiscal Q3 2022 results on May 12, 2022, at 8:30 a.m. EDT. The call will be hosted by CEO Federico Trucco, CFO Enrique Lopez Lecube, and Head of Investor Relations Rodrigo Krause. It will include a presentation and a Q&A session. The company aims to support the transition towards carbon-neutral agriculture with its biotech solutions focused on crop productivity. A replay will be available until May 17, 2022.
Bioceres Crop Solutions Corp. (NASDAQ: BIOX) announced that China’s Ministry of Agriculture has approved the import and use of soybeans produced with its HB4® drought-tolerant technology. This clearance allows for the unrestricted commercialization of HB4® soy, which has already been approved in Argentina, the U.S., Canada, Brazil, and Paraguay, covering approximately 85% of the global soybean trade. Bioceres plans to elaborate on the impact of this approval in its financial results conference call on May 12 at 8:30 am EDT.
Bioceres Crop Solutions Corp. (NASDAQ: BIOX) and Marrone Bio Innovations, Inc. (NASDAQ: MBII) have announced a definitive agreement to merge in an all-stock transaction valued at approximately
Bioceres Crop Solutions Corp. (NASDAQ: BIOX) will attend the 34th Annual ROTH Conference from March 13-15, 2022, at The Ritz Carlton in Laguna Niguel, California. CFO Enrique López Lecube will participate in one-on-one meetings to discuss the company's recent fiscal results for Q2 2022, its HB4 program, and future milestones. This event provides a platform for Bioceres to engage with investors and highlight its innovations aimed at achieving carbon neutrality in agriculture.
Bioceres Crop Solutions Corp. (NASDAQ: BIOX) reported a strong fiscal second quarter 2022, with comparable revenues increasing 89% YoY to $90.3 million and LTM Adjusted EBITDA hitting $61.8 million, up 46%. Revenue growth was driven by inoculants, seed treatments, and micro-beaded fertilizers. The company anticipates peak revenue from HB4 Wheat at $195 million and an EBITDA target of $15-20 million for FY2024. The successful regulatory approval for HB4 wheat flour in Brazil marks a crucial step for commercial launch, with inventories stabilizing towards market demand.
Bioceres Crop Solutions Corp. (NASDAQ: BIOX) will hold a conference call on February 10, 2022, at 8:30 a.m. EST to discuss its fiscal Q2 results for the period ending December 31, 2021. Key executives, including Chairman & CEO Federico Trucco, will present the financial results and engage in a Q&A session. Investors can access the call via a toll-free number or webcast. Details regarding access and a replay of the call will be provided, showcasing Bioceres' commitment to transparent communication with stakeholders.
